Pfizer presents new data on Xeljanz at EULAR 2014

Pfizer is sharing data on the safety and efficacy of its rheumatoid arthritis therapy Xeljanz at a major scientific conference in Paris this week.

The company has had more than ten abstracts accepted for presentation during the European League Against Rheumatism (EULAR) annual meeting, with seven characterising the safety profile of the drug in treating moderately to severely active rheumatoid arthritis.

One of these draws data from an integrated clinical trial database that is based on cumulative exposure in phase II, phase III and open-label long-term extension studies. As such, the analysis covers 5,671 patients with a median exposure of 2.4 years, including more than 500 patients followed for greater than four years.

Dr Steven Romano, global medicines development lead for Pfizer's global innovative pharmaceutical business, said: "Pfizer is proud to showcase our commitment to the ongoing study of Xeljanz, with a focus on further establishing its benefit/risk profile in rheumatoid arthritis."

To date, Xeljanz has been approved in more than 20 countries, with regulatory reviews still ongoing in a more than 35 additional nations.

Last year, a study in the Annals of Internal Medicine revealed that Pfizer's drug can offer various benefits when used in combination with disease-modifying anti-rheumatic drugs.